… In the combination arm, patients received iv vinflunine 280 mg/m 2 on day 1 plus oral …
of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients …

… patients with mild-to-moderate renal impairment [27, 28]. For other treatments such as vinflunine,
pemetrexed and eribulin, PK studies … dose in patients with renal impairment [29, 30, 32]. …

… ) in NSCLC patients who failed at least two regimens of chemotherapy [105]. And a phase I
study recommended safe doses for oral vinflunine … On the other hand, some studies about the …

… , and Vinflunine) as agents in the treatment of hematological and … of action and pharmacokinetic
properties and highlighting … stage of pharmacokinetic, patients with an impaired hepatic …

… for the purpose of second-line treatment [Citation7]. A phase III trial of vinflunine plus best
supportive care … Patients with hepatic dysfunctions are special patient populations worth noting. …

… vinflunine), together with a comprehensive review of the newest preclinical and clinical
investigations on these compounds against breast cancer. … It has a pharmacokinetic profile very …

… the chemotherapeutics vinflunine or taxane-based regimens [Citation4]. Another treatment
… EV101 is a phase I trial evaluating pharmacokinetic characteristics, immunogenicity, safety, …

… Vinflunine will only be a comparator option in countries where vinflunine is approved for
the treatment of metastatic urothelial cancer. Docetaxel will only be a comparator option for …

… Vinflunine ditartrate infused as monotherapy in adult … liver transaminase elevation, however,
clinical liver failure has … favorable pharmacokinetics and stable disease response in 75% of …

… Pharmacokinetic studies were not performed in this study, … dose related (32% of patients
required a dose reduction, which … or vinflunine for previously treated advanced urothelial cancer. …